Form 4: MaxCyte Director Yasir Al-Wakeel Receives Annual Equity Grant

MaxCyte, Inc. Director Yasir B. Al-Wakeel was granted 29,210 Restricted Stock Units and 50,790 stock options as part of the company's annual equity compensation policy for non-employee directors.

Summary

• Yasir B. Al-Wakeel, a Director of MaxCyte, Inc. (MXCT), received an annual equity grant on June 18, 2025.
• The grant included 29,210 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of MaxCyte's Common Stock.
• These RSUs will vest on June 18, 2026, contingent upon Mr. Al-Wakeel's continuous service as a director.
• Additionally, Mr. Al-Wakeel was granted 50,790 stock options with an exercise price of $2.11 per share.
• The stock options are exercisable as of June 18, 2025, and have an expiration date of June 17, 2035.
• Following these transactions, Mr. Al-Wakeel beneficially owns 50,577 shares of Common Stock and 50,790 derivative securities (stock options).
• The grants were made pursuant to MaxCyte's Equity Grant Policy for non-employee directors, with a transaction price of $0 for both the RSUs and options, indicating they were grants, not purchases.

Sentiment

Score: 7

Explanation: The document reports a standard, expected equity grant to a director, which is a positive for aligning interests but does not indicate extraordinary news. The sentiment is neutral to positive due to the routine nature of the compensation.

Positives

• The equity grants align the director's financial interests with those of the shareholders, promoting long-term commitment and performance.
• The grants are part of a standard, disclosed equity compensation policy for non-employee directors, indicating structured corporate governance.

Future Outlook

The 29,210 Restricted Stock Units granted to Director Yasir B. Al-Wakeel are scheduled to vest on June 18, 2026, subject to his continuous service.

Industry Context

This filing represents a routine equity compensation event for a non-employee director, which is a common practice across publicly traded companies, particularly in the biotechnology and life sciences sectors like MaxCyte, Inc., to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to non-employee directors is a standard compensation practice widely adopted by public companies, including those in the biotech industry, to incentivize long-term commitment and align director interests with shareholder returns.
• The structure of the grant, including vesting schedules and option exercise prices, is consistent with typical equity compensation plans for board members in comparable companies, though specific values vary based on company size, performance, and board responsibilities.

Corporate Governance

Related Party Transactions

• The equity grant to Director Yasir B. Al-Wakeel constitutes a transaction with a related party (a director), which is a standard form of compensation for non-employee board members.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's long-term interests with shareholder value creation, as the value of the equity is tied to the company's stock performance.
• Employees: No direct impact mentioned, but a well-governed board can positively influence overall company strategy and employee morale.
• Management: The grant is part of a broader compensation framework that supports effective board oversight and strategic guidance.

Next Steps

• The 29,210 Restricted Stock Units are scheduled to vest on June 18, 2026, provided the reporting person's continuous service.

Key Dates

Keywords

MAXCYTE, MXCT, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Corporate Governance